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AbstrAct:
The number of circulating tumor cells (CTCs) in the peripheral blood of metastatic 
breast cancer patients is now an established prognostic marker. While the central 
nervous system (CNS) is a common site of metastasis in breast cancer, the standard 
marker for disease progression in this setting is cerebrospinal fluid (CSF) cytology. 
However, the significance of CSF cytology is unclear, requires large sample size, is 
insensitive and subjective, and sometimes yields equivocal results. Here, we report 
the detection of breast cancer cells in CSF using molecular markers by adapting 
the CellSearch system (Veridex). We used this platform to isolate and enumerate 
breast cancer cells in CSF of breast cancer patients with central nervous system 
metastases.  The  number  of  CSF  tumor  cells  correlated  with  tumor  response  to 
chemotherapy and were dynamically associated with disease burden. This CSF tumor 
cell  detection  method  provides  a  semi-automated  molecular  analysis  that  vastly 
improves the sensitivity, reliability, objectivity, and accuracy of detecting CSF tumor 
cells compared to CSF cytology. CSF tumor cells may serve as a marker of disease 
progression and early-stage brain metastasis in breast cancer and potentiate further 
molecular analysis to elucidate the biology and significance of tumor cells in the CSF. 
INtrODUctION
In the modern era of oncology, cancer-related 
mortality is associated with metastatic spread rather 
than the voraciousness of the primary tumor [4]. Tumor 
seeding in secondary tissues therefore presents a major 
challenge in cancer treatment [5]. Therapeutic strategies 
are often focused on tumor containment in lieu of 
concerns for tumor cell dissemination into surrounding 
structures. The enumeration of circulating tumor cells 
(CTCs) can monitor the metastatic potential of some solid 
tumors, relate these cells to patient survival, and provide a 
surrogate marker of treatment response [6, 7]. Giving rise 
to the “liquid biopsy”, peripheral blood can be analyzed 
for the presence of CTCs using a range of techniques that 
are in various stages of development [8]. The CellSearch 
system is a CTC detection method that utilizes several 
molecular parameters to isolate CTCs: immunomagnetic 
enrichment for epithelial cell adhesion molecule 
(EpCAM), nuclear staining with 4’, 6-diamidino-2-
phenylindole (DAPI), and immunofluorescence detection 
of cytokeratin and CD45 [9]. Due to its demonstrated 
reliability and prognostic value, the CellSearch system 
is the only CTC detection platform approved by the US Oncotarget 2011; 2:  752 - 760 753 www.impactjournals.com/oncotarget
Food and Drug Administration (FDA) for the enumeration 
of CTCs in metastatic colorectal, prostate, and breast 
cancers.
The  cerebrospinal  fluid  (CSF)  is  an  important, 
unique, and poorly understood compartment of the central 
nervous system (CNS). CSF often acts as a biologic sump 
for neurons and glia and is continuously produced and 
recycled much like blood or lymph, though never filtered. 
Cells from solid tumors can infiltrate the CSF by several 
mechanisms including blood-brain barrier penetration by 
circulating cells, directly through tumor extension along 
Vichow-Robin spaces, or through patterned secondary 
structures of Scherer [10, 11]. Tumor cells within the CSF 
represent a special subpopulation of malignant cells that 
have proven their metastatic potential in peripheral blood 
and may be a source of a number of devastating neurologic 
sequelae. Current methods for examining the CSF involve 
pathological identification of abnormal cells by Wright-
Giemsa stain. With this method there is no quantification 
or characterization of these cells and clinicians must make 
judgments on the binary presence or absence of malignant 
cells as determined by cytology [12]. This is the gold 
standard but lacks molecular analysis and sensitivity, often 
requiring repeat testing or high volume analysis [13]. 
The  prognosis  and  therapeutic  stratification  of 
patients with CNS metastases is currently based on the 
integration of histopathologic data, the appearance and 
severity of neurologic symptoms, and magnetic resonance 
imaging (MRI) of the neuroaxis [14]. To overcome 
limitations of currently available clinical parameters, we 
developed a reliable detection method to enumerate CSF 
tumor cells (CSFTCs) using molecular tumor cell markers 
by adapting the CellSearch system. This report describes 
this detection method and demonstrates the feasibility and 
significance of CTC detection in a pilot study of metastatic 
breast cancer patients with CNS metastases. 
rEsULts
selective detection of breast cancer cells 
One of the diagnostic criteria for CTCs as defined 
by the CellSearch system is to be EpCAM+. We found 
that human glioblastoma cells do not express EpCAM 
contrary to breast cancer cells as expected (Figure 1A). 
Accordingly, spiking these cultured cells into normal 
human blood revealed that the CellSearch system detects 
breast cancer cells but not glioblastoma cells (Figure 1B-
C). This suggests that the CellSearch system could be used 
to detect cancer cells in the CSF that are not of glial origin 
Figure 1: Detection by the cellsearch system of breast cancer cells but not glioblastoma cells present in human blood. 
(A) Western blot analysis of EpCAM expression in SF767 human glioblastoma cells and SKBR3 human breast cancer cells. Ran shown as 
a loading control. (B) Number of CTCs enumerated by CellSearch criteria in normal human blood spiked with 1,000 SF767 and SKBR3 
cells from cell culture. (C) Exemplary image of an SKBR3 cell isolated by the CellSearch system.
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and therefore those with metastatic potential to the CNS. 
Adapting the cellsearch system to detect csFtcs
We  aimed  to  develop  a  method  of  using  the 
CellSearch system to detect tumor cells in CSF. The 
CellSearch uses 7.5 mL of peripheral blood for its standard 
detection method and relies on several checkpoints and 
caveats throughout its processing. One such caveat is 
that the tumor cells will be in the buffy coat following 
centrifugation of the sample. Due to this, CSF cannot 
be directly analyzed in the machine in lieu of blood. We 
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Figure 2: Schematic demonstrating use of the CellSearch system to detect breast cancer cerebrospinal fluid tumor 
cells.  
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Figure 3: Recovery rate of breast cancer cells present in cerebrospinal fluid. (A) Enumeration and (B) recovery rate of 
cultured SKBR3 cells spiked into normal blood (n>3). Oncotarget 2011; 2:  752 - 760 755 www.impactjournals.com/oncotarget
circumvented this by spiking the cellular contents of 
the CSF sample into normal human blood for detection. 
This was accomplished by centrifugation of the CSF and 
resuspension in a small volume of phosphate buffered 
saline  (Figure  2). We  regularly  obtained  normal  blood 
for  these  assays  by  procuring  leukocyte  filters  from 
blood drives and reconstituting normal blood with a 
physiological number of leukocytes. The CSF suspension 
was then spiked into the reconstituted blood and subjected 
to the standard CellSearch protocol. It is noteworthy that 
leukocytes are particularly important for this assay as the 
CellSearch system relies on CTCs and contaminating 
leukocytes when determining the focal plane for 
immunofluorescence analysis. Therefore if a sample with 
no CTCs is analyzed, the CellSearch system will abort the 
analysis if there are no remaining cells present for locating 
the focal plane. 
Accuracy and reproducibility of detecting 
csFtcs 
To characterize the recovery rate and linearity of 
recovery, we spiked cultured breast cancer cells at varying 
cell numbers and determined the recovery rate at these 
various cell counts (Figure 3). We found that the recovery 
rate was ~38%, which is similar to that found in other 
recovery experiments where cultured human tumor cells 
are spiked directly into blood (data not shown). We also 
found this recovery rate to be reproducible and linear 
across the range of cell numbers tested (R2 = .96).
Detection of csFtcs in breast cancer patients 
with cNs metastases and association with disease 
burden 
Five patients with metastatic breast cancer involving 
the CNS were enrolled into a pilot study (Table 1). 
Detecting CSFTCs yielded a number of morphologically 
diverse species that included leukocytes, tumor cells, 
and  significant  amount  of  debris  (Figure  4A).  Note 
that debris is easily separable from tumor cells due to 
the immunostaining for a tumor cell marker and is an 
important advantage because tumor cells may be more 
difficult to distinguish by CSF cytology. Analyzing data 
at baseline and following treatment, there was a general 
inverse  correlation  between  Karnofsky  performance 
Figure 4: Detection of csFtcs in breast cancer patients with cNs metastasis and correlation with Karnofsky 
performance status. (A) Exemplary images of species detected in CSF samples. (B) Correlation of Karnofsky performance status with 
CSFTC number in subjects 1,2, 3, and 5 throughout treatment. (C) Correlation of CSFTCs with CSF cytology results that report positive 
(+), equivocal (?), or negative (-). (D) MRI of subject 5 on day of CSF withdrawal. 
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status (KPS) of and CSFTC number (r = -.66) (Figure 4B). 
There was a general trend toward a higher CSFTC count 
with positive CSF cytology (r = -.37) (Figure 4B), though 
CSF  cytology  clearly  does  not  reflect  disease  burden 
(Figure 4C). Subject 5 had >12,000 CSFTCs and on the 
same day of CSF collection developed status epilepticus 
and deceased. Interestingly this patient showed no gross 
abnormalities by MRI that suggested tumor burden and 
this underscores the importance of CSFTCs as a disease 
marker (Figure 4D). While the correlation between CSFTC 
number and Karnofsky performance shows significance in 
the pilot study, a large cohort of patients will likely reveal 
a stronger significance than can be demonstrated with this 
pilot study.
csFtc count dynamically changes with 
treatment
Response to chemotherapy was evident in three 
patients that were followed over time in this pilot study 
(Figure 5). Subjects 1, 2, and 3 exhibited a significant 
decline in the number of CSFTCs following initiation 
of intrathecal therapy consisting of a combination of 
topotecan, liposomal cytarabine, thiotepa, methotrexate 
and/or trastuzumab (Table 1). It should be noted that at 
several time-points CSF cytology conducted by a blinded 
pathologist gave an equivocal result and that improvements 
in KPS tended to follow a decline in CSFTCs. This data 
clearly highlights the inability of CSF cytology to reflect 
dynamic changes in disease burden. 
In  addition  to  its  general  correlation  with  KPS, 
changes in CSFTC number tended to coincide with 
clinical  deficits.  Prior  to  treatment  initiation,  subject 
2 had >104  CSFTCs and exhibited facial weakness 
and vertical diplopia. These symptoms were resolved 
approximately two months after treatment and was 
accompanied by a near complete disappearance of 
CSFTCs. Subject 3 also harbored >104 CSFTCs and 
suffered from severe vomiting, lethargy, and headaches. 
Following treatment this patient had a CSFTC count that 
declined significantly to 267 CSFTCs but still suffered 
from headaches, though other symptoms resolved. The 
clinical outcome of leptomeningeal or parenchymal CNS 
metastases varies greatly. Patients with an excess of 
10,000 CSFTCs had cranial nerve deficits or mental status 
decline. Two patients showed an improvement in KPS 
after chemotherapy initiation and a concomitant decline 
in  CSFTCs.  Our  findings  from  this  small  pilot  study 
suggest a possible predictive role for CSFTCs and their 
quantification to serve as a reliable marker that reflects 
disease burden dynamically unlike CSF cytology and 
provides information regarding the magnitude of disease 
burden.
Gadolinium-enhanced MRI allows for the sensitive 
visualization of macroscopic changes with the brain, 
spine or leptomeninges. We found an inverse correlation 
with CSFTC count and the presence or enhancement 
pattern seen on such imaging. It should be noted that 
though neuroimaging is an indicator of CNS disease, it 
relies on the breakdown of the blood-brain barrier rather 
than a direct sign of response. Multi-modality imaging 
is an ever-advancing technology but is not sufficient to 
make judgments about cranial and spinal metastases. 
CSFTCs represent a novel marker of CNS disease that 
detects cancer at the single cell level and provides critical 
information to clinicians that attempt to combine cytology, 
imaging and neurologic examination as part and parcel of 
a treatment algorithm. While this study serves as a proof-
of-principle and shows promising significance, a larger 
cohort of patients with follow up studies will be required 
to  concretely  establish  the  prognostic  significance  of 
CSFTC enumeration and the ability of therapeutic agents 
to eliminate these cells.
DIscUssION
The biology of metastases and their relationship 
to the microenvironment of the CNS remains unclear 
[15, 16]. The nature and purpose of malignant cells 
from extraneural sites within the CSF compartment also 
remains unexplored [17]. Our investigation suggests 
that the CSF is a viable source for detecting metastatic 
tumor cells in cancer patients with CNS involvement. 
Table 1: Patient characteristics
Subject Age Her2
Progesterone 
receptor
Estrogen 
receptor
Baseline 
KPS Chemotherapy
1 54 + - - 80 Intrathecal trastuzumab, liposomal 
cytarabine, methotrexate
2 52 - - + 70 Intrathecal liposal cytarabine, 
methotrexate, thiotepa, topotecan
3 28 - - - 60
Intrathecalliposalcytarabine, 
methotrexate, thiotepa, topotecan
4 34 - - - 90 Intrathecalthiotepa, methotrexate, 
topotecan
5 35 - - - 60 Intrathecalthiotepaand topotecanOncotarget 2011; 2:  752 - 760 757 www.impactjournals.com/oncotarget
Micrometastases to the cerebrospinal compartment and 
transmigration through the blood-brain barrier are poorly 
understood events[17-20]. Current anti-cancer therapies 
are relatively successful for local control of breast cancer 
at early stages. However, late-stage and recurrent breast 
cancer often metastasizes to the brain [21]. 
Accurate, early diagnosis and appropriate treatment 
decisions are likely to yield a better patient outcome and 
underscores the importance of accurately monitoring 
common secondary sites by a highly sensitive detection 
method. The ability to detect single cells at a metastatic site 
such as the brain may allow for therapeutic intervention 
that could prevent or destroy metastatic disease an early 
stage [22]. Delays in diagnosis can be disastrous from 
a neurologic standpoint and treatment decisions must 
weigh the risks of aggressive treatment with the extent 
Figure 5: csFtc counts dynamically change with chemotherapy. (A) CSFTC count over time and (B) MRI of subject 1 at 
baseline and days post-treatment initiation. CSFTC count over time in (C) subject 2 and (D) subject 3. (E) MRI of subject 3 at baseline 
(left panel), 42 (middle panel), and 68 days (right panel) post-treatment initiation. (F) MRI of subject 4 at baseline (left panel) and 57 days 
post-treatment initiation (right panel). 
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of disease. As potentiated by the detection of CSFTCs, 
the knowledge that viable cancer remains in the CSF of 
patients is highly useful in making treatment decisions. 
A number of techniques have been developed for 
the isolation of CTCs in peripheral blood since the first 
attempts in the late 1800s [23]. Investigational labs 
now use several different techniques for CTC detection 
including reverse transcriptase polymerase chain reaction, 
immunocytochemistry, flow cytometry, microchips, and 
size-based  filtration  methods  [24-26].  The  CellSearch 
system presents a platform that reliably captures CTCs in 
this setting and provides a semi-automated platform for 
enumerating CTCs based on multiple markers to yield 
high accuracy, recovery, and reproducibility. Several 
studies have demonstrated the clinical significance of CTC 
number as a prognostic marker when enumerated by the 
CellSearch system in metastatic tumors of breast, colon 
and prostate [1, 27, 28]. The isolation and enumeration 
of CSFTCs may provide valuable information for patients 
with CNS metastasis and potentiate studies on the biology 
of these cells and how they differ from the primary and 
metastatic tumor as well as the CTCs found in peripheral 
blood. 
The prognostic relevance of CSFTCs is correlated 
here with the clinical course of the patient and the CSFTC 
count. The biological significance of finding up to several 
thousand CSFTCs in a patient sample remains unclear 
though it is suggestive of and correlates with high disease 
burden. CNS metastases are often strategically located in 
close proximity to ventricular surfaces or CSF cisterns. 
However, natural circulation of CSF can be impaired, 
which may cause “loculations” of malignant CSF, thus 
lowering the diagnostic yield of lumbar puncture [29]. 
Our lab is currently pursuing post-isolation 
characterization of tumor cells isolated from peripheral 
blood as well as CSF [30]. There is an expanding though 
controversial body of evidence that cancer stem cells play 
a large role in the propagation of solid tumors, including 
critical mechanisms of metastasis [31-33]. The reliable, 
sensitive, and accurate isolation of CSFTCs enables such 
studies in conjunction with is potential as a novel marker 
that has clear advantages over CSF cytology. 
MEtHODs
cell culture experiments
Human SKBR3 breast cancer cells were obtained 
from ATCC and cultured in McCoy’s 5A medium 
supplemented with 10% heat-inactivated fetal bovine 
serum and 1% penicillin and streptomycin. Human SF767 
glioma cells were a kind gift from Akiva Mintz (Wake 
Forest University) and were cultured in RPMI under the 
same  conditions.  For Western  blot  analysis,  cells  were 
harvested by cell scraping, centrifuged, and lysed on 
ice for 2 hours. Lysates were harvested and the protein 
concentration was determined using the BioRad protein 
assay. Samples were electrophoresed on 4-12% Bis-Tris 
gels, transferred to PVDF, and blocked in 10% non-fat milk 
in TBST. Membranes were incubated with EpCAM (Cell 
Signaling) at 1:500 or Ran at 1:10,000 (BD biosciences) 
antibodies overnight at 4°C. Membranes were rinsed in 
TBST, incubated with an appropriate HRP-conjugated 
secondary antibody, and visualized using ECL-Plus and 
X-Ray film. 
cell spiking experiments 
Tumor cells were harvested from log-phase growth 
by trypsinization and enumerated using a Cellometer 
(Nexcelom Biosciences) in triplicate. The appropriate 
volume of cell suspension was then added to a tube of 
CSF previously cleared of tumor cell contaminants 
by centrifugation. This CSF was then subjected to the 
standard CSFTC detection procedure described below. 
Patients 
The main inclusion criteria were newly discovered 
breast cancer with metastatic disease involving the CNS 
as confirmed with radiologic or cytologic findings and the 
commencement of intrathecal chemotherapy. All subjects 
provided informed consent for testing of their CSF as 
approved by the Institutional Review Board at the Penn 
State Hershey Medical Center. All subjects were diagnosed 
with primary breast cancer prior to enrollment into this 
study and had undergone neurosurgical intervention in 
terms of placement of a ventricular access device. All 
patients had involvement of the CNS, with combinations 
of parenchymal or leptomeningeal metastases. The 
ventricular access device provided a means to obtain 
CSF for testing. Prior to the onset of treatment, patients 
underwent thorough neurologic examination to identify 
any deficits and were stratified based on KPS. CSF was 
obtained every 2 to 3 weeks for each patient and often 
coincided with intrathecal chemotherapy deposition. The 
neuro-oncologist providing treatment and evaluating the 
patients was blinded to the CSFTC analysis. 
Detection of csFtcs
9mL of CSF was centrifuged at 500g for 10 
minutes, the supernatant was removed, and the pellet 
was resuspended in 1mL of PBS. The suspension was 
then spiked into 6.5mL of reconstituted normal human 
blood.  This  blood  was  obtained  from  leukocyte  filters 
that were generated from blood drives as approved by 
the Institutional Review Board at Penn State Hershey Oncotarget 2011; 2:  752 - 760 759 www.impactjournals.com/oncotarget
Medical  Center.  6.5mL  of  filtered  blood  was  removed 
from the leukocyte trap, placed into a CellSave (Veridex) 
tube, and inverted 8 times. The leukocyte filter was rinsed 
with PBS and back-flushed to obtain leukocytes that were 
enumerated and spiked at 107 cells per 6.5mL sample of 
blood. Samples were analyzed within 3 days using the 
standard CellSearch protocol and the CTC Epithelial Cell 
Kit (Veridex). In brief, the CellSearch system qualifies a 
cell as a CTC if it has an evident nucleus by DAPI staining 
and is EpCAM+, cytokeratin+, and CD45-. Analysis and 
enumeration of CTCs was conducted by a blinded, 
certified assay operator. 
statistics
Bivariate correlation calculated by Pearson’s 
correlation. 
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